4.7 Article

Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against Pseudomonas aeruginosa

Journal

PHARMACEUTICS
Volume 14, Issue 5, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics14050960

Keywords

cystic fibrosis; liposomes; tobramycin; innate defense regulator peptide-1018 (IDR-1018); biofilm; Pseudomonas aeruginosa; multidrug-resistant bacteria

Funding

  1. National Industrial Development and Logistics Program (NIDLP) through the Health Initiative
  2. National Industrial Development and Logistics Program (NIDLP) through the Technology Leader Program Initiative [20-0103, 20-0051]

Ask authors/readers for more resources

This study investigated the susceptibility of Pseudomonas aeruginosa to three antibiotics and an anti-biofilm peptide, and found that liposomes loaded with tobramycin had a significant effect on biofilm formation in the two strains of P. aeruginosa. Furthermore, tobramycin-loaded liposomes showed high therapeutic efficacy and safety for treating lung-infected animal models.
The inadequate eradication of pulmonary infections and chronic inflammation are significant complications in cystic fibrosis (CF) patients, who usually suffer from persistent and frequent lung infections caused by several pathogens, particularly Pseudomonas aeruginosa (P. aeruginosa). The ability of pathogenic microbes to protect themselves from biofilms leads to the development of an innate immune response and antibiotic resistance. In the present work, a reference bacterial strain of P. aeruginosa (PA01) and a multidrug-resistant isolate (MDR 7067) were used to explore the microbial susceptibility to three antibiotics (ceftazidime, imipenem, and tobramycin) and an anti-biofilm peptide (IDR-1018 peptide) using the minimum inhibition concentration (MIC). The most effective antibiotic was then encapsulated into liposomal nanoparticles and the IDR-1018 peptide with antibacterial activity, and the ability to disrupt the produced biofilm against PA01 and MDR 7067 was assessed. The MIC evaluation of the tobramycin antibacterial activity showed an insignificant effect on the liposomes loaded with tobramycin and liposomes encapsulating tobramycin and IDR-1018 against both P. aeruginosa strains to free tobramycin. Nevertheless, the biofilm formation was significantly reduced (p < 0.05) at concentrations of >= 4 mu g/mL and <= 32 mu g/mL for PA01 and <= 32 mu g/mL for MDR 7067 when loading tobramycin into liposomes, with or without the anti-biofilm peptide compared to the free antibiotic, empty liposomes, and IDR-1018-loaded liposomes. A tobramycin concentration of <= 256 mu g/mL was safe when exposed to a lung carcinoma cell line upon its encapsulation into the liposomal formulation. Tobramycin-loaded liposomes could be a potential candidate for treating lung-infected animal models owing to the high therapeutic efficacy and safety profile of this system compared to the free administration of the antibiotic.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available